logo-loader
viewEndocyte Inc

Endocyte Inc shares soar after Novartis pays $2.1 billion for company, shares finish over 50% higher

Novartis will use its resources to develop an Endocyte treatment for prostate cancer

cancer cells
Endocyte is bought out by Novartis for $2.1 billion.

Endocyte Inc (NASDAQ:ECYT) shares rallied by more than 50% by the close of trade on Thursday after it announced it was being bought by Novartis AG for $2.1 billion in cash.

Novartis will acquire all outstanding shares of Endocyte for $24 each, representing a premium of 54% to Endocyte’s closing price of $15.56 on  Wednesday.

Endocyte shares closed on Thursday at $23.40, up 50.39% on the day.

READ: Endocyte shares climb after positive FDA meeting as Wedbush raises price target

Novartis said that, after completing the deal, it will harness its research and expertise to investigate the development of Endocyte's 177Lu-PSMA-617, a radioligand therapy for the treatment of metastatic castration-resistant prostate cancer.

"We are thrilled that Novartis recognizes the potential for 177Lu-PSMA-617 to change the treatment landscape for men with metastatic castration-resistant prostate cancer (mCRPC)," Endocyte CEO Mike Sherman said in a statement.

Endocyte is a biopharmaceutical company developing targeted therapies to treat canceer. The company is based in West Lafayette, Indiana.

Reporting by Rene Pastor, contactable on [email protected]

 

Quick facts: Endocyte Inc

Price: - -

NASDAQ:ECYT
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging achieves positive phase III results in two...

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI)...

2 hours, 9 minutes ago

2 min read